Target: HLA-DR.
Clone: L243.
Specificity: Anti-HLA-DR In Vivo Antibody - Low Endotoxin (L243) recognizes/reacts with the HLA-DR antigen, a member of MHC class II molecules. It does not cross-react with HLA-DP and HLA-DQ.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Antigen Distribution: The HLA-DR antigen is present on B-lymphocytes, activated T-lymphocytes and activated natural killer (NK) lymphocytes. This antigen is also expressed on monocytes, macrophages, human progenitor cells and B-cell lymphomas.
Background: HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kD (heavy) chain & a 27 kD (light) chain. It is expressed on B cells, activated T cells, monocytes/macrophages, and dendritic cells. HLA-DR is critical for efficient peptide presentation to CD4+ T cells. Clone L243 binds a conformational epitope on HLA-DRalpha which depends on the correct folding of the Aβ heterodimer.
Immunogen: Unknown.
Concentration: 1.0 mg/ml.
Formulation: No carrier proteins or preservatives added in 0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4.
Purity: >95% by SDS-PAGE and HPLC.
Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method.
Aggregation: Aggregation level ≤ 5%.
Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.
English
Deutsch
